Costello Medical ISPOR Presentations

**ISPOR 22nd Annual International Meeting, May 2017, Boston, USA**

**PHP266** Value Frameworks to Set Tongues Wagging: Analysis of Opinions and Discussions on Key Value Frameworks  

**PHS131** Inequity in Healthcare Access in Asian Countries with Reportedly High Universal Health Coverage Levels  
Evans J, Ma C, Noon K, Steeves S

**PMD74** Cost-Effectiveness of PET-CT Versus Adrenal Vein Sampling for the Diagnosis of Hypertension Caused by Primary Aldosteronism  
Lin Z, Kusel J, Ghosh W, Brown M

**PMD118** Small and Medium-Sized Enterprises: How Do They Fare in the UK Medical Technologies Evaluation Programme (MTEP)?  
Ridley C, Marsh W

**ISPOR 19th Annual European Congress, November 2016, Vienna, Austria**

**IP7** How Should Biosimilars be Valued and Should They Undergo Health Technology Assessment?  
Kusel J, Psachoulia E, McKenna F, Walker A

**IP21** Is Off-Label Drug Use Enhancing or Limiting Access for Patients with Rare Diseases?  
Griffiths A, Scannell J, Timmis O, Pinilla-Dominguez P

**PRM128** Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: An Exploratory Evaluation Using Advanced Hierarchical Network Meta-Analysis Techniques  

**PRM210** Adapting to the Challenge: How are Innovative Study Designs Being Used in Rare Diseases?  
Berry L, Eddowes L

**PNI70** Health State Utility Values Measured Using the EuroQol 5-Dimensions Questionnaire in Adults with Chronic Hepatitis C: A Systematic Literature Review  
Buchanan-Hughes A, Hanman K, Langford B, Eddowes L

**PHP6** Patient Group Submissions in Health Technology Assessment in Scotland: Prevalence and Impact  
Hamilton K, Hanman K, Griffiths M

**PHP94** Do Scottish Formulary Decisions Match Recommendations Made by the SMC?  
Beale R, Kusel J

**PCV16** Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: A Systematic Literature Review  
PSY156 A Value for Money Threshold for New Technologies for Very Rare Conditions: Does the NI CE Highly Specialised Technology Committee Employ One?
Kusel J, Griffiths A, Spoors J

PCN236 Innovative Therapies for the Treatment of Cancer: An Overview of Late-Phase Clinical Development
Resemann H, Chainani N, Morten P, Griffiths M

PCN294 Reconsidering Drugs Funded via the Cancer Drugs Fund in England: What’s New This Time?
Morten P, Lin Z, Kusel J

PMD23 Cost of Ebola Virus Disease Diagnosis Using Rapid Point-of-Care Diagnostics in Sierra Leone
Evans J, Hearmon N, Beale R, Marsh W

PMD59 Investigating the Cost-Effectiveness of Genetic Counselling for Couples at Known Risk of Having Children with Tay-Sachs Disease: A Two-Generation Model
Ghosh W, Griffiths M, Griffiths A

ISPOR 7th Asia-Pacific Conference, September 2016, Singapore

IP3 Joint HTA: The Next Step for the ASEAN Economic Community?
Chen G, Ngorsurachet S, Redekop K

IP15 Should Productivity Losses due to Illness be Considered in Health Economic Evaluations?
Brooks-Rooney C, Redekop K, Wee HL, Milea D

PCV33 Measurement of Adherence to Anti-Hypertensive Drugs in Asia
Ma Q, Kao C, Miles G, Chen G

PCV54 Quantifying Informal versus Formal Care, and Financial Caregiver Burden, for Stroke Patients in Asia: A Structured Literature Review
Wayman S, Langford B, Buchanan-Hughes A, Chen G

PHP38 Universal Health Coverage in Countries across East and South East Asia - Associations between Health Expenditure and Service Provision
Evans J, Wickstead R, Hanman K, Steeves S

PIN15 Economic Burden of Antibiotic-resistant Nosocomial Gram-Negative Bacteraemia in Singapore Hospitals
Chen G, Lim S, Ma Q, Kao C, Ghosh W

PMH16 Estimating the Economic Impact due to Productivity Losses of Diabetes and Major Depressive Disorder in Singapore: Human Capital versus Friction Cost Approaches
Brooks-Rooney C, Griffiths M, Chen G

ISPOR 21st Annual International Meeting, May 2016, Washington DC, USA

PHP54 The Trade-Off Between QALY Maximisation and Social Values: A Systematic Review of Public Opinion Surveys
Buchanan-Hughes A, Kusel J
PCN323 Does Budget Impact Affect Reimbursement Decisions Made by the Cancer Drugs Fund in England?
Stewart G, Kusel J, Montgomery S

PUK15 Investigating the Cost-Effectiveness of Bacterial Whole-Genome Sequencing for Enabling Targeted Antibiotic Selection in Urinary Tract Infections
Buchanan-Hughes A, Griffiths A, Evans J, Slater D, Eddowes L

PD8116 The Role of Education in the Management of Type 1 Diabetes Mellitus in England
Toth C, Marsh W, Stewart G, Yang L, Bridges H, Kusel J

PRM237 Using Incentives to Improve Health-Related Behaviours: A Review of Incentive-Based Trials
Bunting C, Lim S, Morten P

PRM267 Development of a PRECIS-2 Scoring Grid: How Pragmatic are Pragmatic Trials of Surgical and Pharmaceutical Interventions?
Chen G, Ma Q, Yang L, Ghosh W, Kusel J

PRM55 Hunting for Randomised Controlled Trials (RCTs): A Comparison of Search Filters Designed to Identify RCTs
Steeves S, Buchanan-Hughes A, Evans J, Leonard S

ISPOR 18th Annual European Congress, November 2015, Milan, Italy

ISPOR 5th Latin America Conference, September 2015, Santiago, Chile

IP2 Disinvestment in Latin America: What are the Experiences, Challenges and Proposals for its Successful Implementation?
Agirrezabal I, Rodríguez A, Esandi ME, Gutiérrez-Ibarluzea I

PP4 An Undeveloped Picture: The Availability of Utility Valuations in Latin America. How Will They Affect QALYs?
Montgomery S, Stewart G, Kusel J

PHP23 Pharmaceutical Cost-Containment Strategies - Opinions of the Pharmaceutical Industry and HTA Bodies in Latin America
Beale R, Stewart G, Agirrezabal I, Kusel J

PHP24 Immunisation in Latin America: Factors Preventing Uptake of Cost-Effective Vaccines
Burgon J, Bunting C, Eddowes LA, Wilson T

PHP38 Considerations for the Adoption of the WHO-CHOICE Cost-Effectiveness Threshold in Latin America
Griffiths M, Latchford J, Stewart G, Kusel J

PHP40 Clinical Trial Trends in Latin America: Communicable Versus Non-Communicable Disease
Anderson R, Wilson T

PHP54 Disinvestment Initiatives in Latin America: A Systematic Literature Review
Agirrezabal I, Latchford J, Gutiérrez-Ibarluzea I

PRM9 A Systematic Review of Economic Evaluations in Latin America: Assessing the Factors That Affect Adaptation and Transferability of Results
Stewart G, Slater D, Maruszczak M
PMD34 A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Detecting and Monitoring Outbreaks of MRSA
Agirrezabal I, Buchanan-Hughes A, Eddowes L, Luheshi L, Sagoo GS, Török ME

PMD37 A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Monitoring Outbreaks of Clostridium difficile
Buchanan-Hughes A, Agirrezabal I, Eddowes L, Luheshi L, Török ME, Sagoo GS

PRM28 Implication of the Inter-relatedness of the Proportional and Absolute QALY Shortfall Measurements for Disease Burden
Kusel J, Beale R, Maruszczak M

PHP107 The WHO-Choice Cost-effectiveness Threshold: A Country-level Analysis of Changes Over Time
Griffiths M, Maruszczak M, Kusel J

W5 Value-based Assessment for NICE: How to Do the Calculations
Kusel J, Boysen M, Hatswell AJ, Shah K

HS3 Impact of Morbidity in Populations of North London Clinical Commissioning Groups on Patient Admission Rates and GP Referrals
Groom ZC, Burgon J, Eddowes LA, Wilson T, Kusel J

QA1 Economic Orphans? The Prevalence of Child-specific Utilities in NICE Appraisals for Paediatric Indications
Montgomery S, Hassan M, Kusel J

NI2 Predicting the Impact of Value-based Assessment on Future NICE Appraisals
Beale RC, Maruszczak M, Kusel J

PGI17 A Cost of Care Model for Inflammatory Bowel Disease with a UK NHS Perspective
Miles G, Leonard SA, Ghosh N, Premchand P

PND49 Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis
Maruszczak M, Kusel J, Adlard N

PMH63 Antidepressant Use and Suicide Rate in England: The Geographic Divide
Anderson R, Wilson T, Griffiths M

PRM124 Discrete Event Simulation for the Cost-effectiveness Evaluation of PET-CT Scans in the Diagnosis of Conn’s Disease in Hypertensive Patients
Maruszczak M, Stewart G, Kusel J, Brown MJ

PRM28 Systematic Review and Critique of Health Economic Models of Relapsing-remitting Multiple Sclerosis in the UK
Kusel J, Maruszczak M, Montgomery S, Allen F, Adlard N

PCN260 Investigating the Use of Personalised Medicine in Cancer Trials - An Update
Hamilton K, Wilson T
ISPOR 6th Asia-Pacific Conference, September 2014, Beijing, China

IP2 Disinvestment in Asia-Pacific: How Can This Be Implemented in HTA and What Can Be Learnt from Europe?
Brooks-Rooney C, Kamae I, Tan ST, Gutiérrez-Ibarluzea I

QA2 An Analysis of New Health Technologies and Reimbursement Pricing Structure in Taiwan
Stewart G, Brooks-Rooney C

PCN13 Analysing the Effects of a Disinvestment Decision in Breast Cancer Screening Programmes in Asia-Pacific Countries: A Modelling Approach
Agirrezabal I, Bunting C, Brooks-Rooney C

PCN39 The Differences Between Cancer Drug Approvals in Japan and the USA
Anderson R, Brooks-Rooney C

PDB9 Impact of Ethnicity on the Efficacy and Safety Outcomes of Anti-diabetes Drugs - Case Study of Liraglutide in Asian and Non-Asian Populations

PMS30 Closing the Gap: Reduced Delay to Drug Marketing Approval Between the West and Asia
Hamilton KI, Eddowes LA, Brooks-Rooney C

PIN33 The Differences Between Infectious & Parasitic Drug Approvals in Japan and the USA
Anderson R, Brooks-Rooney C

ISPOR 19th Annual International Meeting, May 2014, Montreal, Canada

HC2 The Impact of NICE's End-Of-Life Threshold on the Availability of New Cancer Therapies in England and Wales
Stewart G, Eddowes L, Hamerslag L, Kusel J

PHP27 An Update on How NICE Manage Off-Label Comparators
Kusel J, Steeves S, Maruszczak M, Pettit L, Wilson T, Taylor D

PGI30 Patterns of Generic and Proprietary Prescribing of Proton Pump Inhibitors (PPIs) Over Time in England
Hamilton K, Kusel J, Leonard S

PDB128 Insulin Pumps for the Treatment of Type 1 Diabetes Mellitus: Why is Uptake so Low in the UK?
Marsh W, Wilson T, Kusel J

ISPOR 16th Annual European Congress, November 2013, Dublin, Ireland

IP13 Should Off-Label Agents Be Used as Comparators in Health Technology Assessments?
Kusel J, Walker W, Spackman E, Andersson C

PCN207 Impact of Recommended Pharmaceuticals on Cancer Mortality: Analysis of Real-Life Data
Wilson T, Hamerslag L, Kusel J

PHP152 The Relationship Between Scientific Research, Clinical Trials and FDA Drug Approval
Burgon J, Hamerslag L

PHP166 How Does the Uncertainty Around the Expected ICER Affect NICE Decisions?
Barber R, Steeves S, Wilson T, Hamerslag L, Kusel J

PMH68 How Well Do We Understand the Economic Burden Associated with Dementia? A Focus on Trends in Care Home Costs and Future Perspectives in the UK
Griffiths M, Hamerslag L, Wilson T, Stewart G, Kusel J

PMS27 Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs
Miles G, Bell J, Wilson T, Hamerslag L, Kusel J
ISPOR 18th Annual International Meeting, May 2013, New Orleans, USA

PSY89 Treatment Options in Obesity: Is Clinical Development Keeping up with an Expanding Population?
Hay J, Barber R, Kusel J, Wilson T

PMS48 Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know?
Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J

PHP104 Assessing the Implementation of NI CE Guidance: Is There a Correlation Between Recommendations and Uptake in Clinical Practice

ISPOR 15th Annual European Congress, November 2012, Berlin, Germany

NI2 The Use of Off-Label Comparators in NI CE Appraisals - An Indirect Endorsement?
Kusel J, Wong GK, Hay JA, Pettit LJ

CA2 Applying a Value-Based Price Across Different Disease Areas
Wilson TJ, Kusel J, Brooks-Rooney C, Costello S

PCN144 Access to Cancer Interventions Across the UK: To What Extent Does SMC Advice Agree with NI CE’s End-of-Life Therapies?
Hamerslag L, Brooks-Rooney C, Zhou A, Pettit L

ISPOR 5th Asia-Pacific Conference, September 2012, Taipei, Taiwan

HC4 Tapping into the Asian Pharmaceutical Market: Global Firms Go Local?

PHP82 The Characteristics of Clinical Trials in Asia
Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S

PRM11 The Use of Biomarkers in Cancer Trials in Asia
Hamerslag L, Wilson T, Brooks-Rooney C

ISPOR 17th Annual International Meeting, June 2012, Washington DC, USA

PCN148 The Use of Personalised Medicine in Cancer Trials

PHP66 Assessing Agreement Between Patient Access Schemes: Review of NI CE and SMC Guidance
Timm B, Leonard S, Haynes S

PRM11 The Rise of Budget Impact Analyses - Another Hurdle in the Health Technology Approval Process?
Wong GKW, Hamer N, Wilson T, Costello S
**ISPOR 14th Annual European Congress, November 2011, Madrid, Spain**

**RS2** Cost-effectiveness of End-of-life, Life-extending Interventions: NICE’s Cost-effectiveness Threshold Explored  
Hammerslag L, Haynes S, Kusel J, Costello S

**RS4** The Interim Cancer Drugs Fund - How To Not Spend £50 Million  

**PHP123** To What Extent Does Advice From the SMC Agree with that Published by NICE?  
Leonard SA, Brooks-Rooney C, Kusel J, Costello S

**PHP145** The Burden of Evidence in the Pharmaceutical Appraisal Process  

**PHP152** The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study  

**PRM9** What Guidance is Available for Budget Impact Analysis?  
Kusel J, Leonard S, Wilson T, Costello S

---

**ISPOR 16th Annual International Meeting, May 2011, Baltimore, MD, USA**

**PRM3** The Burden of Caregiving: Assessing the Status of Current Clinical Research  
Hamer N, Costello S, Hammerslag L, Haynes S, Roper S

**PHP5** Incentive-based Interventions - Rewarding Patients for Good Behaviour  
Haynes S, Costello S, Brooks-Rooney C, Hamer N

**PHP7** Developing Public Health Guidance - What are the Data Gaps? Review of the Gaps in the Evidence Identified by NICE in the UK  
Kusel J, Hamer N, Roper S, Hammerslag L, Costello S

**PHP43** The Influence of Patient Access Schemes on Appraisal Decisions by NICE in the UK  

**PHP89** The Implementation of Public Health Guidance: Preference for Clinical over Behavioural Interventions  
Hammerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S

**PMS69** The Use of Mixed Treatment Comparisons in NICE Technology Appraisals  

---

**ISPOR 13th Annual European Congress, November 2010, Prague, Czech Republic**

**NI4** Do Patient Access Schemes Result in an Acceptable Administrative Burden?  
Haynes S, Costello S, Brooks-Rooney C, Hamer N

**PHP94** Is it Cost-Effective to Change the Behaviour of Healthcare Professionals?  

**PHP98** Cost-Effectiveness Methodologies of Strategies that Aim to Change the Behaviour of Healthcare Professionals  

---

**ISPOR 15th Annual International Meeting, May 2010, Atlanta, GA, USA**

**PHP79** Innovative Pricing Agreements in UK NICE Submissions  
Costello S, Haynes S, Kusel J, Brooks-Rooney C, Hamer N